Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
The Oncologist|February 13, 2015
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human useZahra Hanaizi, Beatriz Flores, Robert Hemmings, et al.
The Oncologist|April 6, 2012
The European Medicines Agency review of cabazitaxel (Jevtana®) for the treatment of hormone-refractory metastatic prostate cancer: summary of the scientific assessment of the committee for medicinal products for human useElias Pean, Pierre Demolis, Alexandre Moreau, et al.
The Oncologist|March 27, 2014
The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human useZahra Hanaizi, Christoph Unkrig, Harald Enzmann, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2011
The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human UseZahra Hanaizi, Barbara van Zwieten-Boot, Gonzalo Calvo, et al.
Hemasphere|July 8, 2021
The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell DiseaseJulio Delgado, Caroline Voltz, Milena Stain, et al.
Hemasphere|July 22, 2021
The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemiaJulio Delgado, Caroline Voltz, Milena Stain, et al.
The Oncologist|October 4, 2011
The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)Petra Matt, Barbara van Zwieten-Boot, Gonzalo Calvo Rojas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2012
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human useElias Pean, Sigrid Klaar, Eva Gil Berglund, et al.
The Oncologist|April 20, 2016
The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseMaria Nieto, Pierre Demolis, Eliane Béhanzin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2013
The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human UseSilvy da Rocha Dias, Tomas Salmonson, Barbara van Zwieten-Boot, et al.
Pageof 8